Klopoxid ”dak”

Chlordiazepoxide, the active ingredient in Klopoxid "dak", is a benzodiazepine presented as a tablet for oral use. It treats anxiety disorders and assists in managing alcohol withdrawal in adult patients. The medication works by enhancing inhibitory neurotransmission, helping to reduce excessive nervous tension and withdrawal symptoms.

GNH USA supplies Klopoxid "dak" as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Chlordiazepoxide is used in the management of anxiety‑related conditions and alcohol‑withdrawal syndromes, acting on the central nervous system.

- Anxiety disorders: reduces excessive worry and tension in adult patients. - Alcohol withdrawal: alleviates symptoms such as tremor, agitation, and risk of seizures during detoxification. - Pre‑operative anxiety: provides sedation and anxiolysis before surgical procedures.

Chlordiazepoxide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: light‑headed sensation, especially when standing quickly. - Impaired coordination: reduced motor control and balance. - Memory impairment: difficulty recalling recent events. - Blurred vision: temporary visual disturbances. - Gastrointestinal upset: nausea or constipation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Dependence or addiction: development of physical or psychological reliance. - Withdrawal seizures: convulsions occurring after abrupt discontinuation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive ideation or self‑harm urges.

When prescribing chlordiazepoxide, clinicians should observe several safety considerations.

- Assess liver function: avoid use in patients with severe hepatic impairment. - Evaluate for substance abuse: caution in individuals with a history of dependence. - Monitor elderly patients: increased sensitivity to sedation and falls. - Review concomitant CNS depressants: adjust doses to prevent excessive sedation. - Pregnancy and lactation: weigh risks versus benefits; limited data available. - Store at ambient temperature: keep below 25 °C in original packaging, protected from moisture.

Chlordiazepoxide can interact with other medicines, altering its effects or safety profile.

Major Interactions (Avoid): - Alcohol: additive CNS depression leading to profound sedation or respiratory compromise. - Opioids or other benzodiazepines: heightened risk of respiratory depression and profound sedation. - Anticholinesterase agents: may reduce the therapeutic effect of chlordiazepoxide.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase sedation; monitor for excessive drowsiness. - Antihistamines: additive sedative effect, requiring dose adjustment. - Oral contraceptives: may alter plasma concentrations of chlordiazepoxide. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): can increase drug levels, necessitating monitoring.